Challenges and Opportunities of Nontraditional Approaches to Treating Bacterial Infections.

Autor:	Tse BN; Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures, Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), US Department of Health and Human Services (US DHHS), Washington, District of Columbia., Adalja AA; Center for Health Security, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.; Division of Infectious Disease, University of Pittsburgh School of Medicine, Pennsylvania., Houchens C; Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures, Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), US Department of Health and Human Services (US DHHS), Washington, District of Columbia., Larsen J; Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures, Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), US Department of Health and Human Services (US DHHS), Washington, District of Columbia., Inglesby TV; Center for Health Security, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland., Hatchett R; BARDA, ASPR, US DHHS, Washington, District of Columbia.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2017 Aug 01; Vol. 65 (3), pp. 495-500.
DOI:	10.1093/cid/cix320
Abstrakt:	Due to increasing rates of antimicrobial-resistant infections and the current inadequacy of the antibiotic pipeline, there is increasing interest in nontraditional approaches to antibacterial therapies. We define "traditional" agents as small-molecule agents that directly target bacterial components to exert a bacteriostatic or bactericidal effect, and "nontraditional approaches" as antimicrobial therapeutics that work through other means (ie, not a small molecule and/or utilizes a nontraditional target). Due to their atypical features, such therapies may be less susceptible to the emergence of resistance than traditional antibiotics. They include approaches such as monoclonal antibodies, virulence disruptors, immunomodulators, phage therapies, microbiome-based therapies, antibiotic potentiators, and antisense approaches. This article discusses both the developmental and regulatory advantages and challenges associated with each of these technologies. By identifying existing regulatory and developmental gaps, we hope to provide a sense of where focusing resources may provide the greatest impact on successful product development. (Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu